Early-stage investor Syncona readjusts priorities due to bleak biotech market
The desolate biotech financing environment is starting to take a toll on investment funds, with the UK life sciences firm Syncona announcing it is realigning its priorities. Syncona will look for ways in which existing ...
The desolate biotech financing environment is starting to take a toll on investment funds, with the UK life sciences firm Syncona announcing it is realigning its priorities.
Syncona will look for ways in which existing ...
